We show for the first time the benefits of using dual inhibitors of ALDH1 and 3 as radiosensitizing agents in chordoma in vitro and provide preclinical support for their use as monotherapies or in combination with radiotherapy in chordoma. This evidence concerns the gene ALDH1A1 and chordoma.